EMA Authorised: Trelegy Ellipta (fluticasone furoate;umeclidinium bromide;vilanterol trifenatate) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

EMA authorised Trelegy Ellipta (fluticasone furoate; umeclidinium bromide; vilanterol trifenatate) for chronic obstructive pulmonary disease, decision date 25 A…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 25/04/2025